The apoptotic efficacy of PI3K inhibitor Alpelisib (BYL719) has also been shown to increase under BRAF-inhibited conditions, suggesting that prolonged BRAF inhibition may lead to increased efficacy of PI3K inhibitors in treating melanoma [227]. Here, BRAF is linked to melanoma.